Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Variants & evidence
1,284 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ALK Amplification + MET Amplification + ROS1 AmplificationALKROS1MET1 | ||||||||
| Crizotinib | Lung Adenocarcinoma | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11386Lung adenocarcinoma cell lines (H3122: EML4-ALK E13:A20, HCC78: SLC34A2-ROS1, H1993: MET amplification, and H596: MET exon 14 skipping) with putative crizotinib-sensitive genotypes were analyzed with … (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC | civic |
| ERBB2 Amplification + MET AmplificationERBB2MET1 | ||||||||
| (diagnostic) | Lung Adenocarcinoma | Diagnostic | B | Supports Positive | 5 | submitted | EID11372This study contained 230 patients presenting with untreated lung adenocarcinoma. Tumor and matched normal material were analyzed via whole-exome sequencing. It was shown that ~62% of samples contained… (full text at CIViC) PMID 25079552 · 2014, Nature · Open in CIViC | civic |
| MET Amplification + MET Exon 14 Skipping Mutation3 | ||||||||
| (prognostic) | Lung Non-Small Cell CarcinomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 5 | submitted | EID11387A study of 687 patients with non-small-cell lung cancer were tested for MET exon splicing mutation or MET amplification. Univariable analysis showed that shorter overall disease-specific survival was … (full text at CIViC) PMID 26847053 · Tong et al., 2016 · Open in CIViC | civic |
| (diagnostic) | Lung Sarcomatoid Carcinoma | Diagnostic | B | Supports Positive | 5 | submitted | EID11388A study of 687 patients with non-small-cell lung cancer were tested for MET exon splicing mutation. In 18 cases with MET exon 14 skipping mutations, 2.6% had adenocarcinoma, 4.8% had adenosquamous cel… (full text at CIViC) PMID 26847053 · Tong et al., 2016 · Open in CIViC | civic |
| Capmatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | ||||||
| MET Amplification + MET Exon 14 Skipping Mutation + ALK Fusion + ROS1 FusionMETALKROS11 | ||||||||
| Crizotinib | Lung Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID1138569 patients with lung adenocarcinoma from Beth Israel Deaconess Medical Center had their cancers submitted for genomic profiling to identify crizotinib-sensitive genomic events. There were 7 cases tha… (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC | civic |
| ATXN7L1 Fusion1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7793Case Report of a a 56-year-old female (never-smoker) patient with stage IV NSCLC. NGS revealed a MET–ATXN7L1 fusion. No additional known driver gene alterations were identified. Following progression … (full text at CIViC) PMID 30339198 · Zhu et al., 2018 · Open in CIViC | civic |
| MET D1010H2 | ||||||||
| Crizotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4792In a lung adenocarcinoma patient harboring MET D1028H mutation, a partial response to crizotinib treatment was reported with continued response for at least 6 months. Prior to crizotinib treatment, th… (full text at CIViC) PMID 25898962 · Waqar et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4793In a lung adenocarcinoma patient harboring a MET D1010H mutation, stable disease to crizotinib monotherapy was reported. The patient was treated with crizotinib for 4 months; treatment was ongoing at … (full text at CIViC) PMID 27343443 · Schrock et al., 2016 · Open in CIViC | civic |
| MET D1010N3 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID6055A female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of crizotinib therapy, a partial resp… (full text at CIViC) PMID 26892698 · Mahjoubi et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4780In a lung adenocarcinoma patient with a MET D1010_splice mutation, a partial response to crizotinib treatment was reported with a 45.1% decrease in tumor measurement by RECIST v1.1. The patient experi… (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Squamous Cell Carcinoma | Predictive | C | |||||
| MET D1010Y1 | ||||||||
| Crizotinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4778In a lung adenocarcinoma patient harboring a MET D1010Y mutation, a partial response to crizotinib monotherapy was reported. The patient was treated with crizotinib for 7 months; treatment was ongoing… (full text at CIViC) PMID 27343443 · Schrock et al., 2016 · Open in CIViC | civic |
| MET D1228N1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 2 | accepted | EID1652Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation. PMID 27343442 · Heist et al., 2016 · Open in CIViC | civic |
| MET D1228V2 | ||||||||
| Cabozantinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1864Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC) PMID 27694386 · Bahcall et al., 2016 · Open in CIViC | civic |
| Savolitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 4 | accepted | EID1865Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savoli… (full text at CIViC) PMID 27694386 · Bahcall et al., 2016 · Open in CIViC | civic |
| MET Exon 14 Mutation2 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7840In a phase 2 trial, patients with NSCLC harboring MET alterations were treated with crizotinib. MET alterations were kinase domain activating mutations included V1110L, H1112L, H1112Y, H1124D, M1149T,… (full text at CIViC) PMID 31932802 · Drilon et al., 2020 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7503In a phase II trial patients with NSCLC harboring with MET amplification or MET exon 14 mutations were treated with multikinase inhibitor crizotinib. MET amplification was defined as MET/CEP7 ration >… (full text at CIViC) PMID 31416808 · Landi et al., 2019 · Open in CIViC | civic |
| MET Exon 14 Skipping Mutation32 | ||||||||
| (prognostic) | Lung Adenosquamous CarcinomaALIAS | Prognostic | C | Supports Poor Outcome | 2 | submitted | EID11411A 33-year old male patient (non-smoker) was diagnosed with Stage IVB adenosquamous lung carcinoma. Various treatment strategies were tried but all had progressive disease quickly after treatment. Next… (full text at CIViC) PMID 33854337 · Jiao et al., 2021 · Open in CIViC | civic |
| Cabozantinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID11400A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. Initial genetic testing showed wild-type EGFR and ALK. She received six cycles of carbo… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC | civic |
| Capmatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | ||||||
Data updated 7 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| B |
| Supports Sensitivity Response |
| 2 |
| submitted |
EID11458Twenty patients with advanced non-small-cell lung cancer (NSCLC) with MET amplification or MET exon 14 skipping mutations were enrolled in this phase II clinical trial. All patients first received cri… (full text at CIViC) PMID 33545388 · Dagogo-Jack et al., 2021 · Open in CIViC |
| civic |
| — |
| submitted |
EID4781In a metastatic lung squamous cell carcinoma patient harboring a MET D1010N mutation, MET D1010N mutation was associated with response to crizotinib monotherapy. The patient maintained initial respons… (full text at CIViC) PMID 27022036 · Heist et al., 2016 · Open in CIViC |
| civic |
| A |
| Supports Sensitivity Response |
| 4 |
| accepted |
EID8847In a phase 2 trial, a total of 364 patients with non-small cell lung cancer and MET alterations were assigned to cohorts based on prior treatment and type of MET alteration. A total of 97 patients, fr… (full text at CIViC) PMID 32877583 · Wolf et al., 2020 · Open in CIViC |
| civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1186A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+. PMID 25971938 · Frampton et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7795An 82 year old with metastatic NSCLC had disease recurrence 39 months after complete surgical resection. Genomic profiling of the primary resection harbored a MET variant c.3028G>C, as well as a frame… (full text at CIViC) PMID 25971938 · Frampton et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11417A 65-year old female (non-smoker) presented with right leg pain and edema. Percutaneous needle biopsy was performed on a mass-like lesion that appeared in a chest x-ray and revealed moderately differe… (full text at CIViC) PMID 36072511 · Kim et al., 2022 · Open in CIViC | civic |
| 〃 | Malignant Lung Neoplasm | Predictive | C | Supports Adverse Response | 3 | submitted | EID11459An 84-year old man (smoker) presented with non-small-cell and small-cell lung cancer harboring MET exon 14 skipping mutations and brain metastases. Patient developed progression after eight months of … (full text at CIViC) PMID 34118303 · Mohan et al., 2022 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Adverse Response | 2 | submitted | EID11409A 68-year old male (former smoker: 50 pack-years) was diagnosed with stage IV lung adenocarcinoma with pleural disseminations and positive intra-abdominal lymph node. Analysis of tumor tissue showed a… (full text at CIViC) PMID 33347701 · Kanemura et al., 2021 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12866H596 cells harboring mutant c-MET due to exon 14 deletion were shown to be sensitive to capmatinib (INCB28060) inhibiting phospho-c-MET in in vitro ELISA studies. IC50s were 0.4 nM for H596 cells. Cap… (full text at CIViC) PMID 21918175 · Liu et al., 2011 · Open in CIViC | civic |
| Carboplatin/Pemetrexed Regimen + PembrolizumabCombination | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11487An 81-year old man (smoker: 40 cigarettes/day) presented with metastatic lung adenocarcinoma. No genetic variants appeared on first round genetic testing on the Oncomine Dx Target TEst Multi-CDx syste… (full text at CIViC) PMID 37007311 · Nitta et al., 2023 · Open in CIViC | civic |
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID11416780 patients with lung cancer were included in this retrospective study. 16 patients with MET mutations were identified, consisting of 7 with MET exon 14 skipping mutations. Analysis of survival of th… (full text at CIViC) PMID 35679833 · Shalata et al., 2022 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7640Patients with non-small cell lung carcinoma harboring MET alterations were treated with crizotinib. MET amplification was defined as more than or equal to 6 copies. The response rate at 2 cycles in pa… (full text at CIViC) PMID 31584608 · Moro-Sibilot et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 1 | accepted | EID7642Pts with MET exon 14-altered NSCLC were enrolled into an expansion cohort of the phase I PROFILE 1001 study (NCT00585195) and received crizotinib. Responses were assessed. By data-cut off 18 pts with … (full text at CIViC) | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID797We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping. PMID 25971939 · Paik et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1185A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib. Exon 14 skipping was detected using qRT-PCR. Response to… (full text at CIViC) PMID 26729443 · Awad et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11384A 68-year old woman (former smoker: 24 pack-years) was diagnosed with advanced lung adenocarcinoma. Genomic profiling yielded MET exon 14 skipping mutation (c.e14 1 G>A), PIK3CA mutation (c.1624 G>A),… (full text at CIViC) PMID 26791794 · Jorge et al., 2015 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11395A 59-year old woman was diagnosed with lung adenocarcinoma after a 15 cm right upper lobe lung mass was found with multiple lymph nodes and pleural nodules. Next-generation sequencing revealed a MET e… (full text at CIViC) PMID 30553716 · Rotow et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11398A 67-year old Asian woman (non-smoker) was diagnosed with stage IV adenocarcinoma with pleural and rib disease. The patient underwent a lobectomy and then received carboplatin/paclitaxel/bevacizumab. … (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1651Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib. PMID 26845194 · Shea et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID7643In this case Report, a 67-year old female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of c… (full text at CIViC) PMID 26892698 · Mahjoubi et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Resistance | 2 | submitted | EID11391A 60-year old woman (non-smoker) was diagnosed with stage IV lung adenocarcinoma after finding a 5.7 x 5.1 cm left pleural-based mass with multiple invasions. The patient was put on carboplatin and pe… (full text at CIViC) PMID 27987579 · Dong et al., 2016 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Does Not Support Sensitivity Response | 2 | submitted | EID11399A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. She received six cycles of carboplatin/pemetrexed which was followed by pemetrexed main… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID11401A 62-year old Asian man (non-smoker) was diagnosed with stage IV adenocarcinoma with pleural metastases. He received pemetrexed, docetaxel, nivolumab, and gemcitabine. Genetic testing revealed MET exo… (full text at CIViC) PMID 30762593 · Wang et al., 2019 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID4786In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12) treated with crizotinib monotherapy, was associated with a response as evident … (full text at CIViC) PMID 25769807 · Jenkins et al., 2015 · Open in CIViC | civic |
| Cabozantinib + CrizotinibSequential | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11410A 77-year old woman was diagnosed with lung adenocarcinoma harboring a MET exon 14 skipping mutation after PET-CT scans showed a right upper lobe mass, right hilar enlarged lymph nodes, and multiple b… (full text at CIViC) PMID 33530219 · Qin et al., 2021 · Open in CIViC | civic |
| Savolitinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11474A 49-year old female (non-smoker) presented with a 3.8 x 2.9 cm mass that was diagnosed as Stage IIIA lung adenocarcinoma. Genetic testing revealed a MET exon 14 skipping mutation, to which the patien… (full text at CIViC) PMID 36052259 · Fu et al., 2022 · Open in CIViC | civic |
| Tepotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID8848In this open-label phase 2 trial, MET inhibitor tepotinib was administered to patients with non-small cell lung cancer and MET exon 14 skipping mutation found in either liquid and/or tissue biopsy. A … (full text at CIViC) PMID 32469185 · Paik et al., 2020 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11766In the VISION phase 2 trial (NCT02864992), 313 patients with advanced, metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations were treated with 500 mg/kg tepotinib daily. In t… (full text at CIViC) PMID 37270698 · Mazieres et al., 2023 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID7272In a interim analysis of Phase II trial for MET exon 14 skipping NSCLC, 34 patients received MEK selective inhibitor tepotinib. 9/15 (60.0%) evaluable patients had a confirmed PR and 3 (20.0%) had SD.… (full text at CIViC) | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID11465A 56-year old male (smoker: 50 pack-years) was diagnosed with stage IIIA lung adenocarcinoma. Patient underwent four cycles of cisplatin and pemetrexed and maintenance therapy with pemetrexed but was … (full text at CIViC) PMID 33387444 · Tanaka et al., 2021 · Open in CIViC | civic |
| 〃 | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11415An 84-year old man (smoker: 62-pack-years) was diagnosed with stage IVB non-small-cell lung cancer (NSCLC) and was started on carboplatin and nab-paclitaxel. After the tumor progressed, the patient wa… (full text at CIViC) PMID 35383870 · Tanaka et al., 2022 · Open in CIViC | civic |
| 〃 | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11476A 57-year female (non-smoker) was diagnosed with lung adenocarcinoma via pleural fluid cytology. After multigene testing revealed MET exon 14 skipping mutation, the patient was switched from cisplatin… (full text at CIViC) PMID 36810936 · Ikeo et al., 2023 · Open in CIViC | civic |